Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Pumpers are in denial mode, they are trying to convince themselves by saying "This shall pass". This company is done, drug is a garbage , has no data to show to world, EMA and FDA filing is a pipe dream.
AUC and odds ratio, what a made up end points. Misleading is a master of manipulating trial data, guys can come up with any kinds of metrics and stats just to suit his narrative. First he design tiny trials, design itself takes him 3-4year, then recruitment is another 5 year affair.
Even Steven Moffat has given up trying to get the keys to the TARDIS back.
Why hold over a volatile weekend a stock that MUST await
real news from efforts that have not yet even been verified?
You calling a bottom?
There is NO reason to catch this falling knife.
There will be EVERY reason to criticize a capital raise at these share prices.
Those people never bought a share. They are pumpers for a reason.
Whatever.
Finance is an INVESTMENT designed as I play the game to increase
the value of my holdings.
There are certainly forces beyond my control in that effort as witnessed by
current global and domestic economic and political events.
IF you can't factor those affects....don't play the game.
The Science of AVXL MAY eventually be vindicated.
There is no evidence at this time it will be soon or is being properly managed.
THOSE assessments are upon which I make MY investment decisions.
Ouija boards, paranoia, and biased unrealistic expectations are not.
Welcome to the 3s and good Luck beating a drum for a non existent catalyst
to limit your losses, let alone reclaim any thoughts of $1M club for some.
i picked up 5000 shares at 3.62
we will watch a little closer now
of course buying again lower is a possibility however hopeful not necessary
What is not known at present is the degree of high frequency trading taking place in money losing reverse splitting paper hanging third tier NASDAQ companies
Or just deploy more of the endless reserves of ever more dry powder?
Xena
Based on your emoji, you disagree that this stock can and should be defended?
We have gone, in less than 4 months, from $9.31 to $3.62. That is wholly factual. Your pedantic argument that this is manipulation notwithstanding, I'm dealing with numerical facts. Is it not a concern, if you are correct, that this equity can be manipulated in such a manner should not be, at least to some degree, concerning?..
Historically there have been a few times when I was deep in the FOMO realm and almost told family members about this great investment opportunity only to have the stock drop 30% the next day. Seriously glad I didn't.
Off to the gym now and will be talking about fishing or baseball while I'm there. lol
Naked shorting just provides the base...
Then they turn the NSS over and over with AI to walk the stock down.
Only the programmers and their bosses know when the pressure will stop.
This is why volatility in the market has gotten worse.
Chasing AVXL lower and lower as an investment strategy has surely been a disaster for some folks here. Longtermbeliever, for example has claimed many times to be buying tens of thousands of shares at a time. bas2020 has also stated many times over the past several years that he and his investment group are “putting dry powder to work” to the tune of tens of thousands of shares. Their collective losses must amount to high six figures if not seven figures. I once knew somebody who bought tens of thousands of shares in a company like Anavex and brought his family, colleagues, and friends into the stock with promises of riches. He even took out a second mortgage on his home to buy the stock. When the stock finally collapsed, he lost his job, he lost friends, and he had family members who would not talk to him. He even had to change gyms because he told all his gym buddies to load up.
And people will still defend him as doing a great job and that they are planning to buy at $1.50. Does that even make sense?
SMH.
They burn $12M per quarter so I don’t think $142M will last more trial failures
Right…
Missling has already booked his European summer break in Greece.
I'm buying at these prices...never know when they will file with EMA or a partnership is announced.
You have been telling same crap since 2015, biggest manipulator is Misleading. When ever he opens up his mouth stock goes down, yesterday's presentation was one of the best he ever did in sleep.
I hate saying it..
But this stock has become impossible to defend
Missling talks, we go down
He stays silent, we go down
Remember, about half the market cap is cash.
Sub $300M MC now….great job, Missling.
Draft guidances can be informally governing, so long as they fall within the range of an Agency's discretion and there are no outstanding rules to the contrary. I have written a draft guidance that was applied in this circumstance, as well as a proposed regulation. Both were procedural.
The FDA's previous Draft Guidance for Alzheimer's (2018) can be downloaded at
https://www.fda.gov/files/drugs/published/Alzheimer%E2%80%99s-Disease---Developing-Drugs-for-Treatment-Guidance-for-Industy.pdf
The link to download the 2024 Draft Guidance can be found here:
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/early-alzheimers-disease-developing-drugs-treatment
The differences between the February 2018 and March 2024 drafts are actually quite subtle. By 2018, the draft guidance already recognized the problem of measuring progression of functional deterioration in early Alzheimer's; that did not begin with the 2024 draft. To understand the differences between the drafts and what the drafts portend for a review of blarcamesine would require careful parsing of one against the other and a good understanding of the FDA's "Stages" of Alzheimer's and in which of those Stages the P2b/3's subjects belong. Since the drafts don't reference any test numbers, like for ADCS-ADL or MMSE, it's hard for me to make that assessment.
Also, both drafts loudly announce
It's not a "bet" at all... It's AI manipulation by entities that can wash trade all day without penalty.
That is the way they create an illusion of selling... "smoke and mirrors" is all it is.
Misleading don't have full AD data, he is just lying. In every conference he is providing clue about his total lies on AD data. WGT crowd will lose everything with their blind trust in TGD.
Which means these low prices again on a risk / reward basis is a good bet
Hey Tred, hope you enjoyed your time off and got what you need from it.
I am starting to think that possibly this is like another we experienced and the price is starting to reflect the true value of the company. On the other hand I do agree that greed drives the world and especially the market.
It certainly is not driven by the desire to help the masses.
Starting several trials this year !
Usually advanced notice is given when announcing the shareholders meeting. It sure appears that they want as few shareholders there as possible. This is one sketchy company. And that's why we sit at 4 year lows - and sinking EVERY SINGLE DAY.
TBSD take your golden parachute and leave
TIME IS UP
NO MORE BS
In the Needham conference his pace was very slow and left little time for questions. The noble conference he had to repeat the same thing several times to make sure he had no time. No desire to answer any questions about law suits or share price.
The old black preacher said" in the bible it says it came to pass it never says it came to stay."
Guess you black out when you write
As clueless as Missling seems (and he seems really clueless), even he has to know that shareholders are angry.
Maybe the BOD will do their job and spare him (and us) of his leadership.
We have a really smart CEO. He sold all @$5.11. Now the SP is $3 something and soon going to $2 something and $1 something. Will George and BASxxx apologize to the board members?
What Missling is saying is that:
1. The fact that our ADL endpoint failed is not a big deal under the new Fed guidelines, given our other endpoint outcomes that were met
2. The EMA is comfortable enough with our results that they allowed us to apply for full approval
What are the chances that one of the “peer reviewers” is communicating to “friends” that the paper is close to completion and looks very promising? Just sayin as BP’s tentacles run deep in research grants. More than one way to cause a delay in bring a novel drug to market.
Still no mention of any upcoming shareholders meeting. I guess their plan is to not have any shareholders left.
Missing would probably be more qualified for a CFO position at some other company not as CEO here. The only hope I see and this may be a huge stretch is Missling holding back releasing AD data until the FDA eases requirements for approval. That is my best effort for cutting this guy some slack.
Noble Capital Markets Virtual Healthcare Equity Conference.
Christopher U Missling, PhD, President & CEO is scheduled to present at
1:30pm ET, TRACK 2 on Thursday, April 18th, 2024.
Guess nobody liked what they heard!
I have ALWAYS gotten the LAST LAUGH even on TSLA & AAPL since Fall 2023.
DIFFERENT STROKES for DIFFERENT FOLKS
PUBLISH THE DATA. STOP THE ARROGANCE. GO TO PLAN B.
EVERYTHING with this company is overdue—especially replacing DM!!
https://www.yahoo.com/lifestyle/signs-of-multiple-sclerosis-can-be-detected-in-blood-5-years-before-symptoms-appear-new-study-finds-heres-why-this-breakthrough-is-important-090015569.html
Early detection + early treatment = positive and prolonged life experiences.
Followers
|
1066
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
458207
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |